Chapter 18. Acute Coronary Syndromes:

- GP IIb/IIIa Receptor Inhibitors

Chapter 107. Drug-Induced Hematologic Disorders:

- Approximately 1% of patients who receive the GPIIb/IIIa receptor antagonist abciximab develop...

Chapter 17. Ischemic Heart Disease:

- Table 17-9 Pharmacologic Management of Percutaneous Coronary Intervention

Chapter 18. Acute Coronary Syndromes:

- Table 18-4 Evidence-Based Pharmacotherapy for ST-Segment Elevation and Non–ST-Segment Elevation Acute Coronary Syndrome

Chapter 107. Drug-Induced Hematologic Disorders:

- Table 107-6 Drugs Associated with Thrombocytopenia

Chapter 54. Blood Coagulation and Anticoagulant, Thrombolytic, and Antiplatelet Drugs:

- Abciximab

- Adverse Effects

Chapter 18. Targeted Drug Delivery Systems and Biotechnological Products:

- Table 18.3 Approved Monoclonal Antibody Drugs and In-Vivo Diagnostics

Chapter 34. Drugs Used in Disorders of Coagulation:

- Abciximab, a chimeric monoclonal antibody directed against the IIb/IIIa complex including...

- Abciximab(ReoPro)

Chapter 55. Immunopharmacology:

- Abciximab is a Fab fragment of a murine-human monoclonal antibody that binds to the...

- Abciximab (ReoPro)

Chapter 109. Disorders of Platelets and Vessel Wall:

- Table 109-1 Drugs Definitively Reported to Cause Isolated Thrombocytopenia^a

Chapter 238. Unstable Angina and Non-ST-Elevation Myocardial Infarction:

- Table 238-2 Clinical Use of Antithrombotic Therapy